Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move

Taking stock of the drug industry, from the lab to the medicine chest

July 16, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kristoffer Tripplaar/Sipa via AP STAT+ | Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move The announcement follows the deaths of two teenagers that forced restrictions on use of the company's gene therapy for Duchenne muscular dystrophy. By Jason Mast and Adam Feuerstein STAT+ | FDA questions safety of GSK's multiple myeloma drug Today's biotech news covers Sino Biopharm buying a Chinese cancer biotech, the departure of Prime's scientific head, and more. By Elaine Chen PEPFAR keeps millions of people with HIV alive and may be spared from Trump spending cuts PEPFAR on Tuesday appeared to be spared a $400 million cut as Republicans acted in rare defiance of a request by President Trump. By Associated Press Adobe STAT+ | Medicare proposes 'efficiency' pay cuts that would hit highly paid specialists the most The proposal would benefit primary care doctors while cutting how much Medicare pays for many tests, procedures, and scans. By Bob Herman and Tara Bannow

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser